HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on MiNK Therapeutics (NASDAQ:INKT) and maintained a $10 price target.
August 10, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on MiNK Therapeutics and maintained a $10 price target.
The reiteration of a 'Buy' rating by HC Wainwright & Co. indicates their continued confidence in MiNK Therapeutics. The maintained price target of $10 suggests they believe the stock is undervalued at current levels. This could potentially lead to increased investor interest and upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100